- Home
- UTMD vs YMAB Comparison
UTMD vs YMAB Comparison
Compare UTMD & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTMD
- YMAB
- Stock Information
- Founded
- UTMD 1978
- YMAB 2015
- Country
- UTMD United States
- YMAB United States
- Employees
- UTMD N/A
- YMAB N/A
- Industry
- UTMD Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- UTMD Health Care
- YMAB Health Care
- Exchange
- UTMD Nasdaq
- YMAB Nasdaq
- Market Cap
- UTMD 178.8M
- YMAB 192.4M
- IPO Year
- UTMD N/A
- YMAB 2018
- Fundamental
- Price
- UTMD $57.80
- YMAB $4.57
- Analyst Decision
- UTMD
- YMAB Buy
- Analyst Count
- UTMD 0
- YMAB 11
- Target Price
- UTMD N/A
- YMAB $17.55
- AVG Volume (30 Days)
- UTMD 20.6K
- YMAB 207.8K
- Earning Date
- UTMD 07-24-2025
- YMAB 08-11-2025
- Dividend Yield
- UTMD 2.11%
- YMAB N/A
- EPS Growth
- UTMD N/A
- YMAB N/A
- EPS
- UTMD 3.78
- YMAB N/A
- Revenue
- UTMD $39,273,000.00
- YMAB $88,658,000.00
- Revenue This Year
- UTMD N/A
- YMAB N/A
- Revenue Next Year
- UTMD N/A
- YMAB $15.15
- P/E Ratio
- UTMD $15.28
- YMAB N/A
- Revenue Growth
- UTMD N/A
- YMAB 4.92
- 52 Week Low
- UTMD $51.26
- YMAB $3.55
- 52 Week High
- UTMD $77.33
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- UTMD 58.57
- YMAB 52.62
- Support Level
- UTMD $54.44
- YMAB $3.90
- Resistance Level
- UTMD $57.74
- YMAB $5.33
- Average True Range (ATR)
- UTMD 1.32
- YMAB 0.39
- MACD
- UTMD -0.02
- YMAB -0.01
- Stochastic Oscillator
- UTMD 75.77
- YMAB 59.87
About UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.